Johnson & Johnson Says Head and Neck Cancer Treatment Given US FDA 'Breakthrough Therapy Designation'

robot
Abstract generation in progress

Johnson & Johnson announced that its head and neck cancer treatment has received ‘Breakthrough Therapy Designation’ from the U.S. FDA. This designation aims to expedite the development and review of drugs for serious or life-threatening conditions. The news was reported by MT Newswires.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)